Cases & Deals

UCB issues €500 million Fixed Rate Bonds under its €5 billion EMTN Programme

Clients UCB S.A.

Jones Day advised UCB S.A. on the update and increase to €5 billion of their EMTN Programme and on the issue of €500 million 1% Fixed Rate Bonds due March 30, 2028 (7Y) thereunder.

UCB S.A. is a global biopharmaceutical company, headquartered in Brussels (Belgium) and listed on Euronext Brussels (ticker: UCBBB). The UCB Group develops and markets human pharmaceutical products for the treatment of severe central nervous system (CNS) and immunology disorders.

The Bonds are issued to strengthen UCB’s balance sheet by partly refinancing the term loan debt incurred in April 2020 in connection with the acquisition of Ra Pharmaceuticals, Inc.

The base prospectus was approved by the Belgian FSMA on March 8, 2021 and is fully compliant with the EU Prospectus Regulation requirements.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.